226 related articles for article (PubMed ID: 25142405)
1. Pharmacological treatment of attention deficit hyperactivity disorder with co-morbid drug dependence.
Cunill R; Castells X; Tobias A; Capellà D
J Psychopharmacol; 2015 Jan; 29(1):15-23. PubMed ID: 25142405
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological and clinical dilemmas of prescribing in co-morbid adult attention-deficit/hyperactivity disorder and addiction.
Pérez de los Cobos J; Siñol N; Pérez V; Trujols J
Br J Clin Pharmacol; 2014 Feb; 77(2):337-56. PubMed ID: 23216449
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, safety and variability in pharmacotherapy for adults with attention deficit hyperactivity disorder: a meta-analysis and meta-regression in over 9000 patients.
Cunill R; Castells X; Tobias A; Capellà D
Psychopharmacology (Berl); 2016 Jan; 233(2):187-97. PubMed ID: 26446868
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder: a meta-regression analysis.
Castells X; Ramos-Quiroga JA; Rigau D; Bosch R; Nogueira M; Vidal X; Casas M
CNS Drugs; 2011 Feb; 25(2):157-69. PubMed ID: 21254791
[TBL] [Abstract][Full Text] [Related]
5. Substance abuse in patients with attention-deficit hyperactivity disorder : therapeutic implications.
Schubiner H
CNS Drugs; 2005; 19(8):643-55. PubMed ID: 16097847
[TBL] [Abstract][Full Text] [Related]
6. Atomoxetine for attention deficit hyperactivity disorder in the adulthood: a meta-analysis and meta-regression.
Cunill R; Castells X; Tobias A; Capellà D
Pharmacoepidemiol Drug Saf; 2013 Sep; 22(9):961-9. PubMed ID: 23813665
[TBL] [Abstract][Full Text] [Related]
7. Discontinuation of pharmacological treatment of children and adolescents with attention deficit hyperactivity disorder: meta-analysis of 63 studies enrolling 11,788 patients.
Riera M; Castells X; Tobias A; Cunill R; Blanco L; Capellà D
Psychopharmacology (Berl); 2017 Sep; 234(17):2657-2671. PubMed ID: 28631099
[TBL] [Abstract][Full Text] [Related]
8. The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review with network meta-analyses of randomised trials.
Catalá-López F; Hutton B; Núñez-Beltrán A; Page MJ; Ridao M; Macías Saint-Gerons D; Catalá MA; Tabarés-Seisdedos R; Moher D
PLoS One; 2017; 12(7):e0180355. PubMed ID: 28700715
[TBL] [Abstract][Full Text] [Related]
9. International Consensus Statement for the Screening, Diagnosis, and Treatment of Adolescents with Concurrent Attention-Deficit/Hyperactivity Disorder and Substance Use Disorder.
Özgen H; Spijkerman R; Noack M; Holtmann M; Schellekens ASA; van de Glind G; Banaschewski T; Barta C; Begeman A; Casas M; Crunelle CL; Daigre Blanco C; Dalsgaard S; Demetrovics Z; den Boer J; Dom G; Eapen V; Faraone SV; Franck J; González RA; Grau-López L; Groenman AP; Hemphälä M; Icick R; Johnson B; Kaess M; Kapitány-Fövény M; Kasinathan JG; Kaye SS; Kiefer F; Konstenius M; Levin FR; Luderer M; Martinotti G; Matthys FIA; Meszaros G; Moggi F; Munasur-Naidoo AP; Post M; Rabinovitz S; Ramos-Quiroga JA; Sala R; Shafi A; Slobodin O; Staal WG; Thomasius R; Truter I; van Kernebeek MW; Velez-Pastrana MC; Vollstädt-Klein S; Vorspan F; Young JT; Yule A; van den Brink W; Hendriks V
Eur Addict Res; 2020; 26(4-5):223-232. PubMed ID: 32634814
[TBL] [Abstract][Full Text] [Related]
10. A randomized controlled trial of pemoline for attention-deficit/hyperactivity disorder in substance-abusing adolescents.
Riggs PD; Hall SK; Mikulich-Gilbertson SK; Lohman M; Kayser A
J Am Acad Child Adolesc Psychiatry; 2004 Apr; 43(4):420-9. PubMed ID: 15187802
[TBL] [Abstract][Full Text] [Related]
11. Extended-Release Mixed Amphetamine Salts vs Placebo for Comorbid Adult Attention-Deficit/Hyperactivity Disorder and Cocaine Use Disorder: A Randomized Clinical Trial.
Levin FR; Mariani JJ; Specker S; Mooney M; Mahony A; Brooks DJ; Babb D; Bai Y; Eberly LE; Nunes EV; Grabowski J
JAMA Psychiatry; 2015 Jun; 72(6):593-602. PubMed ID: 25887096
[TBL] [Abstract][Full Text] [Related]
12. [International Consensus Statement for the Screening, Diagnosis, and Treatment of Adolescents with Concurrent Attention-Deficit/Hyperactivity Disorder and Substance Use Disorder].
Özgen H; Spijkerman R; Noack M; Holtmann M; Schellekens ASA; van de Glind G; Banaschewski T; Barta C; Begeman A; Casas M; Crunelle CL; Daigre Blanco C; Dalsgaard S; Demetrovics Z; den Boer J; Dom G; Eapen V; Faraone SV; Franck J; González RA; Grau-López L; Groenman AP; Hemphälä M; Icick R; Johnson B; Kaess M; Kapitány-Fövény M; Kasinathan JG; Kaye SS; Kiefer F; Konstenius M; Levin FR; Luderer M; Martinotti G; Matthys FIA; Meszaros G; Moggi F; Munasur-Naidoo AP; Post M; Rabinovitz S; Ramos-Quiroga JA; Sala R; Shafi A; Slobodin O; Staal WG; Thomasius R; Truter I; van Kernebeek MW; Velez-Pastrana MC; Vollstädt-Klein S; Vorspan F; Young JT; Yule A; van den Brink W; Hendriks V
Z Kinder Jugendpsychiatr Psychother; 2021 Jan; 50(1):54-67. PubMed ID: 34397296
[TBL] [Abstract][Full Text] [Related]
13. Attention-deficit/hyperactivity disorder and early-onset substance use disorders.
Wilson JJ; Levin FR
J Child Adolesc Psychopharmacol; 2005 Oct; 15(5):751-63. PubMed ID: 16262592
[TBL] [Abstract][Full Text] [Related]
14. Pharmacotherapeutic strategies for the treatment of attention-deficit hyperactivity (ADHD) disorder with comorbid substance-use disorder (SUD).
Perugi G; Pallucchini A; Rizzato S; De Rossi P; Sani G; Maremmani AG; Pinzone V; Maremmani I
Expert Opin Pharmacother; 2019 Feb; 20(3):343-355. PubMed ID: 30513231
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis and treatment of patients with comorbid substance use disorder and adult attention-deficit and hyperactivity disorder: a review of recent publications.
van der Burg D; Crunelle CL; Matthys F; van den Brink W
Curr Opin Psychiatry; 2019 Jul; 32(4):300-306. PubMed ID: 31008730
[TBL] [Abstract][Full Text] [Related]
16. Systematic Review and Meta-Analysis: Treatment of Substance Use Disorder in Attention Deficit Hyperactivity Disorder.
Fluyau D; Revadigar N; Pierre CG
Am J Addict; 2021 Mar; 30(2):110-121. PubMed ID: 33289928
[TBL] [Abstract][Full Text] [Related]
17. Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder.
Biederman J; Wilens T; Mick E; Spencer T; Faraone SV
Pediatrics; 1999 Aug; 104(2):e20. PubMed ID: 10429138
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled, Forced-Dose Clinical Study.
Weisler RH; Greenbaum M; Arnold V; Yu M; Yan B; Jaffee M; Robertson B
CNS Drugs; 2017 Aug; 31(8):685-697. PubMed ID: 28712074
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
20. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
